Ohr Pharmaceutical Promotes Jason S. Slakter, MD to Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Brean Capital Cuts Price Target on Ohr Pharmaceutical (OHRP) Following 3Q Results and Recent Management Changes
August 7, 2015 7:33 AM EDTBrean Capital maintained a Buy rating on Ohr Pharmaceutical (NASDAQ: OHRP), and cut the price target to $30.00 (from $34.00), following 3Q results and recent management changes. Ohr reported EPS of $(0.11) in its FY3Q15, versus consensus of $(0.19). Ohr recently replaced its CEO and founder Irach Taraporewala with CMO Jason Slakter, with Dr. Taraporewala assuming the position of CTO.
Analyst Jonathan Aschoff commented, "Ohr... More
Ohr Pharmaceutical (OHRP) Appoints New CEO
August 5, 2015 8:06 AM EDTOhr Pharmaceutical (Nasdaq: OHRP) announced that Jason S. Slakter, MD, has been appointed Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company's sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company's board of directors.
"We are delighted that Dr. Slakter has agreed to become Chief Executive Officer at Ohr. Since joining the company in 2014, he has shown tremendous leadership in moving our clinical programs... More
